Io Biotech Inc Quick Ratio (IOBT) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Io Biotech Inc   (NASDAQ: IOBT)

Io Biotech Inc 's Quick Ratio

IOBT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 1.67 a new company low.

Within Major Pharmaceutical Preparations industry 240 other companies have achieved higher Quick Ratio than Io Biotech Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 852 to 925.

Explain Quick Ratio?
How much Cash & cash equivalents IOBT´s has?
What are IOBT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IOBT Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change 14.05 % -35.23 % 65.59 % 23.98 % 23.64 %
Y / Y Cash & cash equivalent Change -61.76 % -72.08 % -68.57 % -58.08 % -51.55 %
Quick Ratio MRQ 1.67 3.17 2.03 3.08 4.99
IOBT's Total Ranking # 925 # 852 # 849 # 560 #
Seq. Current Liabilities Change 106.02 % -51.39 % -6.16 % 21.37 % 16.99 %
Seq. Cash & cash equivalent Change 9 % -24.15 % -38.22 % -25.13 % -20.41 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 241
Healthcare Sector # 421
Overall Market # 925


Quick Ratio Statistics
High Average Low
29.22 11.84 1.67
(Mar 31 2022)   (Sep 30 2025)




Financial Statements
Io Biotech Inc 's Current Liabilities $ 18 Millions Visit IOBT's Balance sheet
Io Biotech Inc 's Cash & cash equivalent $ 31 Millions Visit IOBT's Balance sheet
Source of IOBT's Sales Visit IOBT's Sales by Geography


Cumulative Io Biotech Inc 's Quick Ratio

IOBT's Quick Ratio for the trailling 12 Months

IOBT Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 14.92 % 17.29 % 33.44 % 20.77 % 25.94 %
Y / Y Cash & cash equivalent TTM Growth -64.73 % -61.05 % -48.2 % -34.42 % -19.13 %
Quick Ratio TTM 2.4 3.28 4.12 5.95 7.82
Total Ranking TTM # 2390 # 3177 # 3071 # 365 #
Seq. Current Liabilities TTM Growth 3.6 % -7.16 % 12.01 % 6.67 % 5.74 %
Seq. Cash & cash equivalent TTM Growth -24.11 % -26.12 % -22.54 % -18.81 % -16.18 %

Quick ratio ranking by company, industry and sector >> Back to IOBT Financial Strength Comparisons >> Go to Compare IOBT Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2025 to $18.31 millions, cumulative Quick Ratio decreased to 2.4 below the Io Biotech Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Quick Ratio than Io Biotech Inc . While Quick Ratio overall ranking has improved so far to 2390, from total ranking during the twelve months ending second quarter 2025 at 3177.

Explain Quick Ratio?
How much Cash & cash equivalents IOBT´s has?
What are IOBT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 715
Within the Market # 2390


trailing twelve months Quick Ratio Statistics
High Average Low
22.81 11.12 2.88
(Sep 30 2022)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Minerva Neurosciences Inc   4.60 $ 12.287  Millions$ 2.672  Millions
Kura Oncology Inc   4.53 $ 549.665  Millions$ 121.304  Millions
Q32 Bio Inc   4.41 $ 49.039  Millions$ 11.110  Millions
Genelux Corporation  4.38 $ 20.915  Millions$ 4.772  Millions
Assembly Biosciences Inc   4.36 $ 232.557  Millions$ 53.380  Millions
Decoy Therapeutics Inc   4.36 $ 4.810  Millions$ 1.104  Millions
Annexon Inc   4.33 $ 188.721  Millions$ 43.580  Millions
Hutchmed china Limited  4.33 $ 1,367.275  Millions$ 315.775  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Generation Bio Co   4.26 $ 89.622  Millions$ 21.040  Millions
Skye Bioscience Inc   4.22 $ 35.312  Millions$ 8.368  Millions
Dermata Therapeutics Inc   4.20 $ 4.664  Millions$ 1.111  Millions
Lisata Therapeutics Inc   4.16 $ 18.998  Millions$ 4.568  Millions
Enveric Biosciences Inc   4.15 $ 3.758  Millions$ 0.906  Millions
Metsera Inc   4.13 $ 448.461  Millions$ 108.494  Millions
Nektar Therapeutics  4.07 $ 270.208  Millions$ 66.340  Millions
Rhythm Pharmaceuticals Inc   4.01 $ 416.052  Millions$ 103.643  Millions
Adial Pharmaceuticals Inc   3.99 $ 4.606  Millions$ 1.155  Millions
Dogwood Therapeutics inc   3.98 $ 10.127  Millions$ 2.542  Millions
Bioharvest Sciences Inc   3.98 $ 23.025  Millions$ 5.787  Millions
Syndax Pharmaceuticals Inc   3.98 $ 454.174  Millions$ 114.187  Millions
Oragenics Inc   3.97 $ 11.404  Millions$ 2.874  Millions
Maravai Lifesciences Holdings Inc   3.96 $ 243.574  Millions$ 61.574  Millions
Pyxis Oncology Inc   3.93 $ 76.256  Millions$ 19.382  Millions
Enanta Pharmaceuticals Inc  3.89 $ 188.864  Millions$ 48.555  Millions
Sol gel Technologies Ltd   3.89 $ 23.999  Millions$ 6.171  Millions
Larimar Therapeutics Inc   3.89 $ 175.435  Millions$ 45.116  Millions
Entrada Therapeutics Inc   3.88 $ 93.286  Millions$ 24.019  Millions
Bio Green Med Solution Inc   3.83 $ 3.838  Millions$ 1.002  Millions
Rafael Holdings Inc  3.79 $ 45.539  Millions$ 12.013  Millions

Date modified: 2026-09-26T07:41:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.